Volume 26, Number 10—October 2020
Synopsis
Nationwide External Quality Assessment of SARS-CoV-2 Molecular Testing, South Korea
Table 2
Severe acute respiratory syndrome coronavirus 2 external quality assessment panel homogeneity tests of triplicate test results of 3 samples using the NucliSENS easyMAG extraction and Allplex nCoV-2019 kits performed at the Asan Medical Center, Seoul, South Korea, as a proficiency test provider, March 23, 2020*
Sample no. | E gene |
RdRp gene |
N gene |
|||||
---|---|---|---|---|---|---|---|---|
Mean Ct | %CV | Mean Ct | %CV | Mean Ct | %CV | |||
41 | 33.82 | 4.5 | 34.37 | 1.6 | 34.38 | 0.5 | ||
42 | 25.15 | 1.4 | 25.67 | 1.8 | 26.67 | 0.5 | ||
43 | 30.33 | 1.5 | 31.34 | 1.5 | 31.55 | 0.7 | ||
44 | ND | ND | ND | ND | ND | ND | ||
45 | 27.52 | 2.2 | 28.73 | 0.3 | 29.05 | 0.7 | ||
46 | 24.47 | 0.7 | 26.12 | 0.3 | 27.05 | 0.2 | ||
47 | ND | ND | ND | ND | ND | ND | ||
48 | 20.68 | 2.5 | 22.49 | 0.6 | 23.49 | 0.3 | ||
49 | 31.07 | 0.8 | 32.55 | 0.6 | 33.32 | 0.9 | ||
50 | 27.89 | 0.9 | 29.45 | 0.2 | 30.35 | 0.6 |
*Ct, cycle threshold; EQA, external quality assessment; %CV, percentage coefficient of variation; ND, not detected.
1These authors contributed equally to this article.
Page created: July 14, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.